Related Experiment Video
Updated: Nov 4, 2025
13:35
Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
3.3K
Is Sentinel Lymph Node Biopsy Reliable After Recent Oncoplastic Breast Reduction?
Tasha A Martin1, Salman Choudhry2, Luther H Holton3
1Rebecca Fortney Breast Center, Anne Arundel Medical Center, Annapolis, MD, USA.
The American Surgeon
|May 31, 2021
Summary
Sentinel lymph node biopsy (SLNB) is reliable after oncoplastic breast reduction surgery. This study found SLNB feasible with no recurrences, confirming its effectiveness in breast cancer patients.
Area of Science:
- Oncology
- Surgical Oncology
- Breast Surgery
Background:
- Oncoplastic breast reduction can alter lymphatic drainage, potentially impacting sentinel lymph node identification.
- Limited data exists on sentinel lymph node biopsy (SLNB) success rates following recent oncoplastic breast reduction.
- There is no consensus on performing SLNB concurrently with partial mastectomy and reduction for ductal carcinoma in situ (DCIS).
Purpose of the Study:
- To assess the feasibility and identification rate of SLNB after recent oncoplastic or functional breast reduction.
- To evaluate cancer recurrence rates in patients who underwent SLNB after breast reduction surgery.
Main Methods:
- The study evaluated the identification rate of SLNB in patients who had undergone recent breast reduction.
- Recurrence rates were examined in the same patient cohort.
- Follow-up duration averaged 34 months.
Main Results:
- Sentinel lymph node biopsy (SLNB) was found to be feasible in patients who had undergone recent breast reduction.
- At least one sentinel lymph node (SLN) was successfully identified in all patients.
- No instances of cancer recurrence were observed during the follow-up period.
Conclusions:
- Sentinel lymph node biopsy (SLNB) is a viable procedure following oncoplastic or functional breast reduction.
- The findings support the use of SLNB in this patient population, demonstrating high identification rates and no early recurrences.
- Further research may solidify guidelines for SLNB timing in conjunction with breast reduction for DCIS.
